Beckmann M, Tutschek B, Kruger K, Niederacher D, Risse B, Ruppert C, Schnurch H, Bender H
UNIV FRANKFURT,DEPT GYNECOL & ONCOL,FRAUENKLIN,W-6000 FRANKFURT 1,GERMANY.
Int J Oncol. 1993 Aug;3(2):389-97. doi: 10.3892/ijo.3.2.389.
Analyses of the level of expression of the epidermal growth factor receptor (EGF-R) of breast cancer tumors may add independent information about the prognosis of individual patients. Furthermore, the use of monoclonal antibodies directed against EGF-R as therapeutic tools (e.g., Mab 425) requires a reliable evaluation of the individual EGF-R content. Various analytical methods have been published, including (Scarff RW and Torloni H: World Health Organization, Geneva, 1968), biochemical detection of EGF-R by a radiolabeled physiologic ligand [I-125]EGF, (Early Breast Cancer Trialists' Collaborative Group: Lancet 329: 1-15, 1992) biochemical analyses of EGF-R content with a monoclonal antibody, and (McGuire WL and Clark GM: N Engl J Med 326: 1756-1761, 1992) immunohistochemical EGF-R detection. We measured the EGF-R content in membrane pellets derived from routine processing for evaluation of estrogen (ER, ER-EIA) and progesterone receptor (PgR; PgR-EIA) in 185 breast cancers and 18 benign breast samples, using a single-point saturation assay (RBA). Simultaneously, ER (ER-ICA), PgR (PgR-ICA), and EGF-R immunohistochemistry was performed on frozen sections of the same tumors. Various cell lines and normal skin tissue samples served as EGF-R positive or negative controls. The results of the two different EGF-R analyzing methods were compared with other biological characteristics of the tumors. 37% of the tumors were EGF-R positive. There was an inverse correlation between the ER or PgR and the EGF-R content. EGF-R overexpression correlated with high tumor grade. Analyses of EGF-R content in membrane pellets of breast cancer samples by single point saturation assay as well as the evaluation of tumor sections by immunohistochemistry can be performed routinely. The results obtained with both analytical methods did not differ significantly. but the immunohistochemistry proved to be more difficult to perform and to interpret. Thus, we prefer to perform both analytical methods simultaneously to provide information potentially useful for clinical management of individual cancer patients.
对乳腺癌肿瘤表皮生长因子受体（EGF-R）表达水平的分析，可能会为个体患者的预后增添独立的信息。此外，将针对EGF-R的单克隆抗体用作治疗工具（例如，Mab 425），需要对个体的EGF-R含量进行可靠评估。已经发表了多种分析方法，包括（斯卡夫RW和托尔洛尼H：世界卫生组织，日内瓦，1968年），通过放射性标记的生理配体[I-125]EGF对EGF-R进行生化检测，（早期乳腺癌试验协作组：《柳叶刀》329：1 - 15，1992年）用单克隆抗体对EGF-R含量进行生化分析，以及（麦圭尔WL和克拉克GM：《新英格兰医学杂志》326：1756 - 1761，1992年）免疫组织化学检测EGF-R。我们使用单点饱和分析法（RBA），对185例乳腺癌和18例良性乳腺样本常规处理后获得的膜沉淀中的EGF-R含量进行了测量，这些样本用于评估雌激素（ER，ER-EIA）和孕激素受体（PgR；PgR-EIA）。同时，对相同肿瘤的冰冻切片进行了ER（ER-ICA）、PgR（PgR-ICA）和EGF-R免疫组织化学检测。各种细胞系和正常皮肤组织样本用作EGF-R阳性或阴性对照。将两种不同的EGF-R分析方法的结果与肿瘤的其他生物学特征进行了比较。37%的肿瘤EGF-R呈阳性。ER或PgR与EGF-R含量之间呈负相关。EGF-R过表达与高肿瘤分级相关。通过单点饱和分析法对乳腺癌样本膜沉淀中的EGF-R含量进行分析，以及通过免疫组织化学对肿瘤切片进行评估，均可常规进行。两种分析方法获得的结果没有显著差异，但免疫组织化学证明更难实施和解读。因此，我们倾向于同时进行两种分析方法，以提供可能对个体癌症患者临床管理有用的信息。
